Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/25387
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHeald, AH-
dc.contributor.authorMartin, S-
dc.contributor.authorFachim, H-
dc.contributor.authorGreen, HD-
dc.contributor.authorYoung, KG-
dc.contributor.authorMalipatil, N-
dc.contributor.authorSiddals, K-
dc.contributor.authorCortes, G-
dc.contributor.authorTyrrell, J-
dc.contributor.authorWood, AR-
dc.contributor.authorBeaumont, RN-
dc.contributor.authorFrayling, TM-
dc.contributor.authorDonn, R-
dc.contributor.authorNarayanan, RP-
dc.contributor.authorOllier, W-
dc.contributor.authorGibson, M-
dc.contributor.authorYaghootkar, H-
dc.date.accessioned2022-10-27T12:43:31Z-
dc.date.available2022-10-27T12:43:31Z-
dc.date.issued2021-01-27-
dc.identifiere14531-
dc.identifierORCiD ID: Hanieh Yaghootkar - https://orcid.org/0000-0001-9672-9477.-
dc.identifier.citationHeald, A.H. et al. (2021) 'Genetically defined favourable adiposity is not associated with a clinically meaningful difference in clinical course in people with type 2 diabetes but does associate with a favourable metabolic profile', Diabetic Medicine, 38 (9), e14531, pp. 1 - 11. doi: 10.1111/dme.14531en_US
dc.identifier.issn0742-3071-
dc.identifier.urihttps://bura.brunel.ac.uk/handle/2438/25387-
dc.descriptionData availability statement: We used patient-level data which was fully anonymised prior to analysis. Any requests for access to the Salford data should be made to Dr Adrian Heald.en_US
dc.description.abstractCopyright © 2021 The Authors. Aims Change in weight, HbA1c, lipids, blood pressure and cardiometabolic events over time is variable in individuals with type 2 diabetes. We hypothesised that people with a genetic predisposition to a more favourable adiposity distribution could have a less severe clinical course/progression. Methods We involved people with type 2 diabetes from two UK-based cohorts: 11,914 individuals with GP follow-up data from the UK Biobank and 723 from Salford. We generated a ‘favourable adiposity’ genetic score and conducted cross-sectional and longitudinal studies to test its association with weight, BMI, lipids, blood pressure, medication use and risk of myocardial infarction and stroke using 15 follow-up time points with 1-year intervals. Results The ‘favourable adiposity’ genetic score was cross-sectionally associated with higher weight (effect size per 1 standard deviation higher genetic score: 0.91 kg [0.59,1.23]) and BMI (0.30 kg/m2 [0.19,0.40]), but higher high-density lipoprotein (0.02 mmol/L [0.01,0.02]) and lower triglycerides (−0.04 mmol/L [−0.07, −0.02]) in the UK Biobank at baseline, and this pattern of association was consistent across follow-up. There was a trend for participants with higher ‘favourable adiposity’ genetic score to have lower risk of myocardial infarction and/or stroke (odds ratio 0.79 [0.62, 1.00]) compared to those with lower score. A one standard deviation higher score was associated with lower odds of using lipid-lowering (0.91 [0.86, 0.97]) and anti-hypertensive medication (0.95 [0.91, 0.99]). Conclusions In individuals with type 2 diabetes, having more ‘favourable adiposity’ alleles is associated with a marginally better lipid profile long-term and having lower odds of requiring lipid-lowering or anti-hypertensive medication in spite of relatively higher adiposity.en_US
dc.description.sponsorshipDiabetes UK. Grant Number: 17/0005594; European Research Council. Grant Number: 323195.en_US
dc.format.extent1 - 11-
dc.languageEnglish-
dc.language.isoen_USen_US
dc.publisherJohn Wiley & Sons Ltd on behalf of Diabetes UKen_US
dc.rightsCopyright © 2021 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. This is an open access article under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subjectBMIen_US
dc.subjectectopic faten_US
dc.subjectfavourable adiposity genetic scoreen_US
dc.subjectHbA1cen_US
dc.subjectmetabolic profileen_US
dc.subjectmyocardial infarctionen_US
dc.subjectstrokeen_US
dc.subjecttype 2 diabetesen_US
dc.titleGenetically defined favourable adiposity is not associated with a clinically meaningful difference in clinical course in people with type 2 diabetes but does associate with a favourable metabolic profileen_US
dc.typeArticleen_US
dc.identifier.doihttps://doi.org/10.1111/dme.14531-
dc.relation.isPartOfDiabetic Medicine-
pubs.issue9-
pubs.publication-statusPublished-
pubs.volume38-
dc.identifier.eissn1464-5491-
dc.rights.holderThe Authors-
Appears in Collections:Dept of Life Sciences Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdf439.93 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons